Prestige Consumer Healthcare (NYSE:PBH) Sets New 52-Week Low - Here's Why

Key Points

• Prestige Consumer Healthcare's stock recently hit a new 52-week low, trading as low as $62.92, and closed at $62.84 with a volume of 40,915 shares.
• Several analysts have downgraded the stock, with Zacks Research changing their rating from "hold" to a "strong sell" and Canaccord Genuity lowering its target price from $105 to $100 while maintaining a "buy" rating.
• The company reported earnings per share (EPS) of $0.95 for the last quarter, missing consensus estimates of $1.01, along with a revenue drop of 6.6% compared to the previous year.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) shares reached a new 52-week low during trading on Monday . The stock traded as low as $62.92 and last traded at $62.84, with a volume of 40915 shares trading hands. The stock had previously closed at $63.25.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Zacks Research cut shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th. Wall Street Zen cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of "Hold" and a consensus price target of $93.33.

Prestige Consumer Healthcare Stock Performance

The firm has a market cap of $3.11 billion, a price-to-earnings ratio of 14.81, a price-to-earnings-growth ratio of 2.03 and a beta of 0.46. The stock's 50 day moving average is $69.07 and its 200 day moving average is $78.49. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The business had revenue of $249.53 million during the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The business's revenue for the quarter was down 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in PBH. Cetera Investment Advisers bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $413,000. Focus Partners Wealth bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at approximately $235,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Prestige Consumer Healthcare by 4.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,201 shares of the company's stock valued at $2,202,000 after purchasing an additional 1,080 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Prestige Consumer Healthcare by 8.9% in the 4th quarter. Quantinno Capital Management LP now owns 9,013 shares of the company's stock valued at $704,000 after purchasing an additional 739 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in Prestige Consumer Healthcare by 44.4% in the 4th quarter. ProShare Advisors LLC now owns 14,925 shares of the company's stock valued at $1,165,000 after purchasing an additional 4,590 shares during the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.